Janet Britt - Amedisys VP Collections
| AMED Stock | USD 99.31 0.81 0.82% |
Insider
Janet Britt is VP Collections of Amedisys
| Phone | 225 292 2031 |
| Web | https://www.amedisys.com |
Amedisys Management Efficiency
The company has return on total asset (ROA) of 0.0652 % which means that it generated a profit of $0.0652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0667 %, meaning that it created $0.0667 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD JD | Acadia Healthcare | N/A | |
| Barbara CPA | InnovAge Holding Corp | 61 | |
| David CFA | Acadia Healthcare | N/A | |
| Andrew Brophy | Healthcare Services Group | 34 | |
| J Abernathy | National HealthCare | 83 | |
| L Shaw | Encompass Health Corp | 75 | |
| Matthew MBA | Healthcare Services Group | N/A | |
| Melanie Lewis | Encompass Health Corp | N/A | |
| Christopher Hunter | Acadia Healthcare | 57 | |
| Matthew Peterson | Universal Health Services | 55 | |
| Anthony Hernandez | Encompass Health Corp | 59 | |
| Dan Peoples | Enhabit | N/A | |
| Carl Adams | National HealthCare | N/A | |
| Andrew Honeybone | Acadia Healthcare | N/A | |
| Vicki Dodson | National HealthCare | 63 | |
| Maria Lozzano | InnovAge Holding Corp | 44 | |
| Crissy Carlisle | Enhabit | 52 | |
| Laurence Harrod | Acadia Healthcare | 67 | |
| JD Kennedy | InnovAge Holding Corp | 64 | |
| Rob Borella | InnovAge Holding Corp | N/A | |
| John Gochnour | Pennant Group | 42 | |
Management Performance
| Return On Equity | 0.0667 | ||||
| Return On Asset | 0.0652 |
Amedisys Leadership Team
Elected by the shareholders, the Amedisys' board of directors comprises two types of representatives: Amedisys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amedisys. The board's role is to monitor Amedisys' management team and ensure that shareholders' interests are well served. Amedisys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amedisys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael North, Senior Vice President - Operations | ||
| John Nugent, Chief Officer | ||
| Pete Hartley, CTO Systems | ||
| Kendra Kimmons, VP Relations | ||
| Jennifer Griffin, Chief Secretary | ||
| Janet Britt, VP Collections | ||
| Francis Mayer, Senior Development | ||
| Keith Blanchard, Acting Officer | ||
| Richard Ashworth, CEO President | ||
| Scott CPA, COO, VP | ||
| Allyson Guidroz, Chief Officer | ||
| Scott Ginn, Chief Accounting Officer | ||
| Denise Bohnert, Chief Officer | ||
| Paul Kusserow, CEO and President and Director | ||
| Caitlin Franklin, Acting Officer | ||
| Nick Muscato, Vice President of Strategic Finance | ||
| Adam Holton, Chief Officer |
Amedisys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amedisys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0667 | ||||
| Return On Asset | 0.0652 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 3.35 B | ||||
| Shares Outstanding | 32.89 M | ||||
| Shares Owned By Insiders | 1.95 % | ||||
| Shares Owned By Institutions | 92.50 % | ||||
| Number Of Shares Shorted | 2.24 M | ||||
| Price To Earning | 15.03 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.